CN118355033A - 包含抗NRP2a抗体的组合物和方法 - Google Patents

包含抗NRP2a抗体的组合物和方法 Download PDF

Info

Publication number
CN118355033A
CN118355033A CN202280080506.0A CN202280080506A CN118355033A CN 118355033 A CN118355033 A CN 118355033A CN 202280080506 A CN202280080506 A CN 202280080506A CN 118355033 A CN118355033 A CN 118355033A
Authority
CN
China
Prior art keywords
cancer
antigen
antibody
optionally
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280080506.0A
Other languages
English (en)
Chinese (zh)
Inventor
卢克·G·博尔曼
张宇婷
凯特琳·劳奇
莱斯利·A·南格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
aTyr Pharma Inc
Original Assignee
aTyr Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by aTyr Pharma Inc filed Critical aTyr Pharma Inc
Publication of CN118355033A publication Critical patent/CN118355033A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2863—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CN202280080506.0A 2021-10-27 2022-10-27 包含抗NRP2a抗体的组合物和方法 Pending CN118355033A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163272374P 2021-10-27 2021-10-27
US63/272,374 2021-10-27
PCT/US2022/078780 WO2023076998A1 (en) 2021-10-27 2022-10-27 COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES

Publications (1)

Publication Number Publication Date
CN118355033A true CN118355033A (zh) 2024-07-16

Family

ID=86158721

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280080506.0A Pending CN118355033A (zh) 2021-10-27 2022-10-27 包含抗NRP2a抗体的组合物和方法

Country Status (7)

Country Link
US (1) US20240417476A1 (cg-RX-API-DMAC7.html)
EP (1) EP4423142A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024540083A (cg-RX-API-DMAC7.html)
CN (1) CN118355033A (cg-RX-API-DMAC7.html)
AU (1) AU2022375785A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234409A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023076998A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019195770A1 (en) 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
AU2020358854B2 (en) 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7420040B2 (en) * 2006-02-24 2008-09-02 Arius Research Inc. Cytotoxicity mediation of cells evidencing surface expression of TROP-2
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
NZ594514A (en) * 2009-03-05 2013-06-28 Abbott Lab Interleukin-17 BINDING PROTEINS
JP5812418B2 (ja) * 2009-04-17 2015-11-11 イムナス・ファーマ株式会社 Aβオリゴマーに特異的に結合する抗体およびその利用
EP2700652B1 (en) * 2011-04-18 2018-12-19 The University of Tokyo Diagnosis and treatment of cancer using anti-itm2a antibody
DK2935331T3 (en) * 2012-12-24 2018-06-06 Abbvie Inc PROLACTIN RECEPTOR BINDING PROTEINS AND APPLICATIONS THEREOF
EP3116906A1 (en) * 2014-03-12 2017-01-18 Prothena Biosciences Limited Anti-laminin4 antibodies specific for lg1-3
US11104724B2 (en) * 2016-05-23 2021-08-31 New York University Compositions and methods for antibodies targeting staphylococcal leukotoxins
US12365916B2 (en) * 2017-10-30 2025-07-22 Miltenyi Biotec B.V. & Co. KG Adapter-based retroviral vector system for the selective transduction of target cells
WO2019195770A1 (en) * 2018-04-06 2019-10-10 Atyr Pharma, Inc. Compositions and methods comprising anti-nrp2 antibodies
MX2021011489A (es) * 2019-04-01 2021-10-22 Jiangsu Hengrui Medicine Co Anticuerpo anti-claudina 18.2 y utilizacion del mismo.
ES3049416T3 (en) * 2019-09-23 2025-12-16 Centro Nac De Investigaciones Cardiovasculares Carlos Iii F S P Antibodies for the diagnosis and/or treatment of atherosclerosis
AU2020358854B2 (en) * 2019-10-03 2026-08-13 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
WO2021202590A1 (en) * 2020-03-31 2021-10-07 Alector Llc Anti-mertk antibodies and methods of use thereof

Also Published As

Publication number Publication date
AU2022375785A1 (en) 2024-04-11
WO2023076998A1 (en) 2023-05-04
EP4423142A1 (en) 2024-09-04
JP2024540083A (ja) 2024-10-31
CA3234409A1 (en) 2023-05-04
EP4423142A4 (en) 2025-10-22
US20240417476A1 (en) 2024-12-19

Similar Documents

Publication Publication Date Title
US12065495B2 (en) Compositions and methods comprising anti-NRP2 antibodies
CN114746120B (zh) 包含抗nrp2抗体的组合物和方法
US20180282402A1 (en) Anti-hrs antibodies and combinaton therapies for treating cancers
JP2024075762A (ja) Nrp2関連疾患を治療するための組成物および方法
US20240417476A1 (en) COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2a ANTIBODIES
WO2021257808A2 (en) Antibodies to fibroblast activation protein and b7h3
US20250188170A1 (en) COMPOSITIONS AND METHODS COMPRISING ANTI-NRP2b ANTIBODIES
HK40008971B (en) Monovalent asymmetric tandem fab bispecific antibodies

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB03 Change of inventor or designer information
CB03 Change of inventor or designer information

Inventor after: Luke G. Borman

Inventor after: Zhang Yuting

Inventor after: Caitlin lauch

Inventor after: Leslie Ann Green

Inventor before: Luke G. Borman

Inventor before: Zhang Yuting

Inventor before: Caitlin lauch

Inventor before: Leslie A. Nagel